Combination therapy slows pancreatic cancer progression in preclinical models

April 19, 20241 min
Closeup of ultrasound diagnostics. Examination of pancreas, left lobe and liver with convex probe

Galectin-3 (GAL3), which regulates cell proliferation and the function of various immune cell populations, is highly expressed by myeloid and pancreatic cancer cells. However, its role in the pancreatic tumor microenvironment remains unclear.

To provide further insights, researchers led by Yang Chen, Ph.D., generated in vivo models of pancreatic cancer with GAL3 genetically deleted in both cancer and myeloid cells. Deleting GAL3 inhibited pancreatic cancer progression and prolonged survival in these models. Single-cell sequencing revealed that GAL3 deletion enriched antitumor myeloid cells, and it also resulted in upregulation of CXCL12 as a possible compensatory mechanism for cancer progression. Inhibiting both CXCL12 and GAL3 enhanced anti-PD1 immunotherapy treatment response, highlighting the combination’s potential as a therapeutic strategy for patients with pancreatic cancer.

MJH footer logo with red letters

Medical Journal – Houston is the leading source of healthcare business news. With extremely relevant content, late-breaking news and monthly exclusives from industry experts, MJH News has created a winning combination of must-read editorial that physicians and hospital executives eagerly anticipate month after month. MJH News is the resource that provides everything they need in one place, and it is a high honor that they rely upon Medical Journal – Houston to keep their practice or hospital on the cutting edge.

Archives